High lot-to-lot consistency
Increased sensitivity and higher affinity
Animal-free production
Description:
Anti-PDL1, AlpHcAbs® Human antibody is designed for detecting human PDL1 specifically. Anti-PDL1, AlpHcAbs® Human antibody is recombinant VHH domain of alpaca IgG2b/2c fused to Human IgG1 Fc. Based on ELISA, Anti-PDL1, AlpHcAbs® Human antibody reacts with human PDL1, and has reactivity with cynomolgus PDL1.
Immunogen: Recombinant human PDL1
Host: Alpaca pacous
Isotype: VHH domain of alpaca IgG2b/2c fused to Human IgG1 Fc(mutation)
Conjugate: Unconjugated
Specificity: Human PDL1
Cross-Reactivity: Cross-reactivity with cynomolgus PDL1
Purity: Recombinant Expression and Affinity purified
Concentration: 1mg/ml
Formation: Liquid, 10mM PBS (pH 7.5), 0.05% sucrose, 0.1% trehalose, 0.01% proclin300, 50% Glycerol
Storage: Store at –20 °C, (Avoid freeze / thaw cycles), Stable for 12 months at -20°C
Background:
Programmed death receptor ligand 1 (PD-L1), also known as CD274 or B7H1, is a recently described B7 family member. To date, one specific receptor has been identified that can be ligated by PD-L1. This receptor, programmed death receptor 1 (PD-1), has been shown to negatively regulate T-cell receptor (TCR) signaling. Upon ligating its receptor, PD-L1 has been reported to decrease TCR-mediated proliferation and cytokine production. PD-L1 expression was found to be abundant on many murine and human cancers and could be further up-regulated upon IFN-gamma stimulation. Thus, PD-L1 might play an important role in tumor immune evasion.
Using antibody with Fc(mutation), the background from Fc receptors will be eliminated.
ELISA: 1:4,000-1:10000
Flow Cytometry：1:200-1:1000
Dilution factors are presented in the form of a range because the optimal dilution is a function of many factors, such as antigen density, permeability, etc. The actual dilution used must be determined empirically.
